Skip to main content

Table 3 Multivariate logistic regression analyses for SCR and SPR

From: Immunogenicity and safety of quadrivalent influenza vaccine among young and older adults in Tianjin, China: implication of immunosenescence as a risk factor

 

SCR

Pre-vaccination SPR

Post-vaccination SPR

aOR (95% CI)

P

aOR (95% CI)

P

aOR (95% CI)

P

H1N1

 Age, years

0.971 (0.944–0.999)

0.042

0.996 (0.965–1.027)

0.794

0.964 (0.923–1.007)

0.096

 IV history

0.153 (0.064–0.366)

 < 0.001

7.794 (3.452–17.595)

 < 0.001

0.357 (0.114–1.112)

0.076

 Pre-vaccination HAI

0.997 (0.988–1.007)

0.598

——

——

1.184 (1.089–1.287)

 < 0.001

H3N2

 Age, years

0.998 (0.971–1.027)

0.908

1.007 (0.974–1.040)

0.693

1.019 (0.985–1.053)

0.274

 IV history

0.691 (0.312–1.533)

0.363

1.655 (0.694–3.946)

0.256

0.574 (0.231–1.425)

0.231

 Pre-vaccination HAI

0.911 (0.877–0.946)

 < 0.001

——

——

1.063 (1.014–1.115)

0.012

B/Victoria

 Age, years

0.964 (0.937–0.992)

0.011

1.017 (0.986–1.050)

0.286

0.948 (0.901–0.997)

0.038

 IV history

0.919 (0.413–2.044)

0.835

2.21 (0.980–4.985)

0.056

0.329 (0.092–1.170)

0.086

 Pre-vaccination HAI

0.973 (0.958–0.989)

0.001

——

——

1.153 (1.052–1.264)

0.002

B/Yamagata

 Age, years

0.985 (0.956–1.016)

0.343

0.93 (0.898–0.963)

 < 0.001

0.742 (0.550–1.001)

0.051

 IV history

0.381 (0.170–0.855)

0.019

5.868 (2.357–14.610)

 < 0.001

0.013 (0.000–10.369)

0.203

 Pre-vaccination HAI

0.983 (0.972–0.994)

0.003

——

——

1.27 (0.981–1.643)

0.069

  1. Abbreviations: SCR Seroconversion rate, SPR Seroprotection rate, CI Confidence interval, aOR Adjusted odds ratio (adjusted for male sex, number of days after vaccine administration for blood sample collection, and common comorbid conditions including hypertension, hyperlipidemia, coronary heart disease, and diabetes mellitus), IV history influenza vaccination history in the previous year, HAI Hemagglutination inhibition antibody titer